Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS)

CONCLUSION: Abiraterone acetate and apalutamide presumably are associated with a higher risk of MACE than enzalutamide in new-generation ARPI for prostate cancer. More extensive prospective studies and more extended follow-up periods need to confirm this further.PMID:37482524 | DOI:10.1016/j.clgc.2023.07.003

Source: Clinical Prostate Cancer - July 23, 2023 Category: Cancer & Oncology Authors: Yang Liu Hui-Min Zhang Yu Jiang Zhi Wen Er-Hao Bao Jing Huang Chong-Jian Wang Cai-Xia Chen Jia-Hao Wang Xue-Song Yang Source Type: research